quinoxalines has been researched along with Parkinsonian Disorders in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Avegno, EM; Borgkvist, A; Hen, R; Kheirbek, MA; Sonders, MS; Sulzer, D; Wong, MY | 1 |
| Beal, MF; Faust, K; Gehrke, S; Lu, B; Yang, L; Yang, Y | 1 |
| Ali, U; Chen, L; Gui, ZH; Hui, YP; Li, Q; Liu, J; Wang, T; Wang, Y; Zhang, QJ | 1 |
| Blume, SR; Caballero, A; Cass, DK; Dec, A; Park, DJ; Park, MJ; Sammut, S; Simak, N; Sunu, E; Tseng, KY; West, AR | 1 |
| Fujimaru, S; Matsubara, K; Ohtaki, K; Saito, O; Shimizu, K; Shiono, H | 1 |
| Bonastre, M; Chase, TN; Jimenez, A; Marin, C; Tolosa, E | 1 |
6 other study(ies) available for quinoxalines and Parkinsonian Disorders
| Article | Year |
|---|---|
Loss of Striatonigral GABAergic Presynaptic Inhibition Enables Motor Sensitization in Parkinsonian Mice.
Topics: Adrenergic Agents; Animals; Bacterial Proteins; Channelrhodopsins; Corpus Striatum; Disease Models, Animal; Dopamine; Excitatory Amino Acid Antagonists; GABA Agents; GABAergic Neurons; gamma-Aminobutyric Acid; Humans; Inhibitory Postsynaptic Potentials; Luminescent Proteins; Medial Forebrain Bundle; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Pyridinium Compounds; Quaternary Ammonium Compounds; Quinoxalines; Substantia Nigra | 2015 |
Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease.
Topics: Age Factors; Animals; Animals, Genetically Modified; Anti-Inflammatory Agents; Antioxidants; Brain; Cell Count; Cell Survival; Chromatography, High Pressure Liquid; Dopamine; Drosophila; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagonists; Immunohistochemistry; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinsonian Disorders; Pentacyclic Triterpenes; Quinoxalines; Triterpenes; Ubiquinone | 2009 |
Noradrenergic lesion of the locus coeruleus increases the firing activity of the medial prefrontal cortex pyramidal neurons and the role of alpha2-adrenoceptors in normal and medial forebrain bundle lesioned rats.
Topics: Action Potentials; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Brimonidine Tartrate; Locus Coeruleus; Male; Medial Forebrain Bundle; Neurotoxins; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Prefrontal Cortex; Pyramidal Cells; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Yohimbine | 2010 |
Inhibition of striatal soluble guanylyl cyclase-cGMP signaling reverses basal ganglia dysfunction and akinesia in experimental parkinsonism.
Topics: Animals; Basal Ganglia; Corpus Striatum; Cyclic GMP; Enzyme Inhibitors; Guanylate Cyclase; Male; Mice; Mice, Inbred C57BL; Oxadiazoles; Parkinsonian Disorders; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Soluble Guanylyl Cyclase | 2011 |
Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport Proteins; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Extracellular Space; Glutamic Acid; Herbicides; Homovanillic Acid; Male; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Nerve Tissue Proteins; Neuroprotective Agents; Neurotoxins; NG-Nitroarginine Methyl Ester; Nitric Oxide; Paraquat; Parkinsonian Disorders; Quinoxalines; Rats; Rats, Wistar; Selegiline | 2003 |
Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Dextromethorphan; Excitatory Amino Acid Antagonists; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Piperazines; Quinoxalines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Riluzole; Rotation | 2000 |